

491. Severe asthma and developing allergy in childhood

4708

Bronchoscopy and endobronchial biopsies in children: Useful or not?

Fardou Heida¹, Marielle Pijnenburg², Leonie Vanlaeken², Wim Timens¹, Bart Rottier¹. ¹Pediatric Pulmonology, University Medical Center, Groningen, Netherlands; ²Pediatric Pulmonology, Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands

Introduction: Bronchoscopy and endobronchial biopsies are diagnostic tools in the evaluation of difficult asthma and other paediatric airway diseases. The yield of these procedures in clinical practice is uncertain. Therefore our aim was to evaluate if bronchoscopy and endobronchial biopsies change management.

Methods: Retrospectively we collected data on diagnosis and treatment before and after bronchoscopy in all children undergoing bronchoscopy with endobronchial biopsies between 0 and 18 yrs. Difficult asthma was defined as uncontrolled asthma despite high dose ICS dose and LABA. In endobronchial biopsies reticular basement membrane (RBM) thickness was measured.

Results: Of the 74 children (37 male, mean age 7.8 yrs), 26 had asthma and 13 had difficult asthma. The diagnosis of children undergoing bronchoscopy changed in 31.3% of the cases: 10 children got a second diagnosis, which could explain the persistent symptoms, 8 children were misdiagnosed. In these 18 children airway malacia (n=10) and anatomic abnormalities (n=7) were the most common. In 9.5% of the cases biopsies changed the diagnosis; in 3 of them ciliary dyskinesia was suspected. In 25% medication was changed after bronchoscopy.

Children without asthma had a RBM of 5.6 µm [SD ±1.4]; in children with asthma RBM thickness was 5.11 µm [SD ±1.05] and in those with difficult asthma 6.0 µm [SD ±1.34] (p=0.49).

Conclusion: Bronchoscopy showed an important role to reveal underlying causes of persistent symptoms such as airway malacia and anatomic abnormalities. In 25% of patients bronchoscopy led to a change in treatment. We found no significant difference in RBM thickness between nonasthmatic, asthmatic children and children with difficult asthma.

4709

IL-33 and airway remodelling in paediatric severe therapy resistant asthma

Nicola Ullmann^{1,2}, Alex Adams^{1,2}, Cara J. Bossley^{1,2}, Tim Oates^{1,2}, Claire M. Lloyd², Andy Bush¹, Sejal Saglani^{1,2}. ¹Paediatric Respiriology, Royal Brompton Hospital, London, United Kingdom; ²Leukocyte Biology, Imperial College London, London, United Kingdom

Background: Associations have been reported between epithelial interleukin (IL)-33 expression and severe asthma in adults, but its role in the pathophysiology of paediatric severe therapy resistant asthma (STRA) remains unknown.

Objectives: We quantified IL-33 expression in endobronchial biopsies from children with STRA and explored its relationship with parameters of airway remodelling.

Methods: Children (n=45) (median age 11.3 [range 5.4-16.4] years) with STRA underwent detailed investigations including bronchoscopy and endobronchial biopsy. IL-33+ cells were quantified in the epithelium, smooth muscle and submucosa in biopsies from children with STRA and compared to that in age matched non-asthmatic controls. Reticular basement membrane (RBM) thickness was quantified as a marker of airway remodelling, and related to IL-33+ cells.

Results: Submucosal, but not epithelial or smooth muscle IL-33+ cells were significantly higher in children with STRA compared to controls (p=0.01, 0.21, 0.68 respectively).

In addition, there was a positive correlation between IL-33+ cells and RBM thickness in children with STRA (Spearman r=0.35, p=0.018), but not in controls (p=0.33).

Conclusions: In contrast to adult studies, we have shown increased submucosal IL-33 expression in children with STRA, and for the first time have shown an association between this mediator and airway remodelling. These data suggest therapies that block IL-33 may be suitable for paediatric STRA, and specifically may impact on structural airway changes.

4710

Exhaled nitric oxide in children with severe asthma

Jon Konradson^{1,2}, Björn Nordlund^{1,2}, Christophe Pedroletti³, Kjell Alving³, Gunilla Hedlin^{1,2}. ¹Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; ²Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden; ³Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden

Introduction: Exhaled nitric oxide (FE_{NO}) is a biomarker of eosinophilic airway inflammation, but the relationship between FE_{NO} and asthma severity is uncertain. We compared FE_{NO} normalized against reference values (%FE_{NO}) in children with

Problematic severe (PA) and controlled (CA) asthma and investigated whether increased %FE_{NO} is associated with morbidity, irrespective of predefined severity classification.

Methods: Children with PA had recurrent symptoms despite treatment with ≥800 µg Budesonide, those with CA had few symptoms with 100-400 µg. The protocol included Asthma control test, spirometry (%), methacholine provocation (dose response slope), FE_{NO} (p.p.b.), computerized tomography (CT) of the lungs (PA only) and blood sampling for eosinophils (10⁹ x L⁻¹) and IgE (kU/L). The difference between measured and expected FE_{NO} (Ln(FE_{NO}) = 0.0112 x height (cm) + 0.641) were given in percentages (%FE_{NO}).

Results: Children with PA (n=57, age 13y) had a trend towards higher levels of FE_{NO} and %FE_{NO} compared to children with CA (n=39, age 14y): 22 (10-40) vs. 17 (9-26), p=0.13 and 210% (101-367) vs. 139% (85-216), p=0.07, respectively. When analysing all children (n=96), those with %FE_{NO}>200 had reduced asthma control (18.5 (17-20) vs. 20.4 (19-22), p=0.04) and FEV1/FVC (77 (74-81) vs. 83 (81-86), p=0.004) and increased bronchial hyperresponsiveness (54 (5-67) vs. 2 (0.4-36), p=0.001), bronchial wall thickening on CT (25 (21-29) vs. 17 (14-19), p=0.004), eosinophils (0.5 (0.4-0.6) vs. 0.3 (0.2-0.3), p<0.001) and IgE (539 (253-1525) vs. 140 (43-425), p<0.001) compared to those with %FE_{NO}<200.

Conclusion: Children with high levels of %FE_{NO} have increased morbidity which is partly independent of predefined severity classification.

4711

Fungal sensitisation in children with severe therapy resistant asthma

Susana Castanhinha¹, Atul Gupta^{2,3}, Marco Magliana⁴, Sergio Koo⁵, Cara Bossley², Louise Fleming², Andrew Bush^{2,3}, Sejal Saglani^{2,3}. ¹Department of Paediatrics, Hospital Santa Maria, Universidade de Lisboa, Lisbon, Portugal; ²Department of Respiratory Medicine, Royal Brompton and Harefield NHS Trust, London, United Kingdom; ³National Heart and Lung Institute, Imperial College, London, United Kingdom; ⁴Department of Paediatrics, Federico II University, Naples, Italy; ⁵Department of Paediatrics, Queen Mary Hospital, Chinese University of Hong Kong, China

Adults with severe asthma with fungal sensitisation (SAFS) have reduced lung function and increased morbidity [Am J Respir Care Med 2009;179:11-18]. We hypothesized that fungal sensitisation in children with severe, therapy-resistant asthma (STRA) is associated with increased morbidity.

Methods: All children had STRA having had basic management optimized [Lancet 2010;376:814-25]. There were 166 patients (11.7 years [4-17]; 61% boys). SAFS (n=76) was defined as specific IgE (spIgE) or skin prick test (SPT) positivity to *Aspergillus fumigatus*, *Alternaria alternata* or *Cladosporium herbarum*. Non-sensitized patients (n=90) had negative spIgE and SPT. Age, atopy, symptoms, medication, lung function and airway inflammation were assessed.

Results: SAFS children were mainly boys (57/76 (75%) vs 43/90 (48%), p<0.001), had earlier asthma onset (0.5 years [0-12.5] vs 1.5 [0-12.5], p=0.006), higher total IgE (637 IU/mL [12-6737] vs 177 [1-10881], p=0.002) and sum of inhalant allergen SPT and spIgE (16 mm [0-38] vs 9 [0-36], p<0.001; 78 IU/mL [0-400] vs 19 [0-243], p=0.02). SAFS children had a trend for lower FEV1 (72%Pred [29-121] vs 75.5 [23-125], p=0.18) and FVC (90%Pred [36-138] vs 95 [30-123] p=0.13), more bronchodilator reversibility (59/73 (81%) vs 42/81 (52%), p<0.001), and were more likely prescribed maintenance oral steroids (18/76 (24%) vs 8/88 (9%), p=0.02). Symptoms and airway inflammation (sputum, bronchoalveolar lavage and endobronchial biopsy) were similar.

Conclusions: Children with STRA and SAFS had earlier asthma onset, more atopy and bronchodilator reversibility, and were more often given prednisolone. We need a randomised controlled trial of antifungal therapy in paediatric SAFS.

4712

Urinary eicosanoids and preschool wheeze phenotype

Mubin Ibrahim¹, Chinedu Nwokoro¹, Marek Sanak², Hitesh Pandya⁴, Steve Turner³, Jonathan Grigg¹. ¹Centre for Paediatrics, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, Greater London, United Kingdom; ²University Department of Medicine, Jagellonian University School of Medicine, Kraków, Poland; ³Department of Child Health, University of Aberdeen, United Kingdom; ⁴Department of Child Health, University of Leicester, United Kingdom

Rationale: Preschool wheeze follows two broad clinical patterns; i) multi-trigger wheeze (wheeze both with and between colds) and ii) episodic viral wheeze (wheeze exclusively with colds). Whether these patterns reflect stable, distinct phenotypes with different underlying inflammation remains unclear.

Hypothesis: We hypothesised that preschool children with multi-trigger wheeze have chronic pulmonary leukotriene activation, and therefore higher baseline urinary eicosanoids, than episodic viral wheezers.

Methods: Children aged 10 months to 5 years with wheeze and no respiratory comorbidity were recruited from three UK hospitals. Wheezing pattern was obtained from parental history. Urine was collected between viral-triggered attacks and frozen at -70°C. Samples were analysed using high performance liquid chromatography tandem mass spectrometry for a range of eicosanoids (Table 1).

Results: See Table 1. There was no significant demographic difference between multi-triggered (n=46) and episodic (n=115) wheezers. There was no significant difference in baseline eicosanoid excretion between the 2 groups (P=NS by unpaired t-test, Table 1).

Table 1. Baseline urinary eicosanoids (pg/mg of creatinine)

	Episodic	Multitrigger
Leukotriene E4	1216.47	928.71
13,14-dihydro-15-keto-PGE2	455.03	625.38
13,14-dihydro-15-keto-PGD2	198.32	245.59
13,14-dihydro-15-keto-tetranor-PGE2	1281.95	1837.72
13,14-dihydro-15-keto-tetranor-PGD2	2108.84	1845.95
tetranor-PGE-M	35655.09	34995.67
tetranor-PGD-M	45810.02	43065.58
15-deoxy-delta12,14-PGJ2	361.61	606.20
9a,11b-PGF2	695.37	872.18

Conclusions: We found no evidence that the multi-trigger phenotype is associated with increased baseline eicosanoid activation.
Dedicated to the memory of Prof Andrzej Szczeklik who would have been a co-author.

4713

Changes in skin prick test (SPT) from the age of 1 to 6 years (yrs) and relationship to specific IgE and atopic dermatitis: The French arm of PASTURE European study

Amandine Chauveau¹, Marie Laure Dalphin¹, Vincent Kaulek², Stéphanie Drillon¹, Anne Leydier¹, Caroline Roduit³, Erika von Mutius⁴, Dominique Angèle Vuitton⁵, Jean Charles Dalphin². ¹Pediatrics, University Hospital, Besançon, France; ²Respiratory Disease, University Hospital, Besançon, France; ³Pediatrics, University of Zurich, Children's Hospital, and Christine Kühne-Center for Allergy Research and Education, Zurich, Switzerland; ⁴Pediatrics, University Children's Hospital, Munich, Germany; ⁵EA 3181, University of Franche-Comte, Besançon, France

The "PASTURE" study (Protection against Allergy: STudy of Rural Environment) examines the influence of exposure to a dairy-farm environment on the occurrence of allergy in a cohort of European children from the 3rd trimester of pregnancy to 10-yrs.

The aim of this study was to analyze the course of SPTs to aero- and food allergens from the age of 1 to 6 yrs in the french children of PASTURE, whether they live or not on a farm and to evaluate their relationship to specific IgE and atopic dermatitis (AD).

Two hundred and four french children, which 95 of the farmer group, were included. SPTs, AD assessment and specific IgE assays were performed at 1, 4.5 and 6 yrs.

One hundred and forty children participated in all three visits. The prevalence of positive SPTs increased with age (9.5% at 1 yr, 14.2% at 4.5 yrs, 22.6% à 6 yrs). It was lower in the farmer group, regardless of age and category of allergens considered (statistically significant only for seasonal allergens at 4.5 yrs). Positive SPTs were transient at 1 yr whereas they were persistent between 4.5 and 6 yrs. The prevalence of AD was not significantly different in the two groups and decreased with age. Positive SPTs at 1 yr were predictive of the occurrence of AD during the follow-up. The correlation between SPTs and specific IgE was poor for an IgE cut-off at 0.35UI/mL but increased with age and with higher cut-off.

In conclusion, our study showed that skin reactivity (1) increased with age, (2) was lower in the farmer group, (3) at 1 yr was transient but predictive of the occurrence of AD. Correlation between SPTs and specific IgE was poor, especially at one yr.

4714

DNA methylation in asthma and allergy related genes is influenced by farm exposure and time trends in early childhood

Sven Michel¹, Florence Busato², Jon Genuneit³, Juha Pekkanen⁴, Charles Dalphin⁵, Josef Riedler⁶, Nicolas Mazaleyrat², Erika von Mutius⁷, Juliane Weber⁷, Charlotte Braun-Fahrlander^{8,9}, Roger Lauener^{10,11}, Michael Kabesch¹, Jörg Tost², the PASTURE Study Group. ¹Department of Pediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany; ²Laboratory for Epigenetics, Centre National de Génotypage, CEA-Institut de Génomique, Evry, France; ³Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany; ⁴National Institute for Health and Welfare, THL Kuopio, Kuopio, Finland; ⁵Department of Respiratory Disease, Université de Franche-Comté, Besançon, France; ⁶Children's Hospital Schwarzbach, Children's Hospital Schwarzbach, Schwarzbach, Austria; ⁷University Children's Hospital, LMU, Munich, Germany; ⁸Institute of Social and Preventive Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland; ⁹University of Basel, University of Basel, Switzerland; ¹⁰Children's Hospital and Christine Kühne-Center for Allergy, University of Zürich, Switzerland; ¹¹Christine Kühne-Center for Allergy Research and Education, Hochgebirgsklinik Davos, Davos-Wolfgang, Switzerland

Genes and environmental influences are crucial for the development of asthma and atopic diseases. These factors may act upon each other through epigenetic mechanisms.

We studied the rural birth cohort PASTURE (Protection against allergy: study in rural environments) to investigate if (a) epigenetic patterns in asthma candidate genes are influenced by farm exposure in general and (b) change over the first years of life and (c) whether these changes may contribute to the development of asthma.

DNA was extracted from cord blood and whole blood at age 4.5 in 48 samples per time point. We analyzed DNA methylation of 23 regions in ten asthma and allergy candidate genes (*ORMDL1*, *ORMDL2*, *ORMDL3*, *CHI3L1*, *RAD50*, *IL13*, *IL4*, *STAT6*, *FOXP3* and *RUNX3*) by pyrosequencing and compared differences between strata.

In cord blood, regions in *ORMDL1* and *STAT6* showed a hypomethylation while regions in *RAD50* and *IL13* were hypermethylated when DNA from farmers was compared to non-farmers (lowest p-value 0.001 for *STAT6*). Only small associations between asthma status and methylation were observed in our population. Changes in methylation over time occurred in 14 out of 23 gene regions investigated (lowest p-value for *IL13*, $p=1.57 \times 10^{-8}$). Interestingly, these differences clustered in the genes highly associated with asthma (*ORMDL* family) and IgE regulation (*RAD50*, *IL13* and *IL4*) but not in the T-regulatory genes (*FOXP3*, *RUNX3*).

Our study indicates that DNA methylation changes significantly in early childhood in specific asthma and allergy related genes in peripheral blood cells while also early exposure to farm life seems to influence methylation patterns in certain genes.

4715

Does breastfeeding influence development of atopy? A cohort study

Cristian Dogaru¹, Aniña Pescatore¹, Ben Spycher¹, Caroline Beardsmore², Michael Silverman², Claudia Kuehni¹. ¹Institute for Social and Preventive Medicine, University of Bern, Switzerland; ²Department of Infection, Immunity & Inflammation, University of Leicester, United Kingdom

Aim: It has been postulated that breastfeeding (BF) reduces the risk of allergy in children. However, recent studies failed to show a protective effect or suggested an increased risk of atopy with BF. We examined the association between BF and atopy, measured by skin prick test (SPT), in a large population-based cohort, stratifying by maternal hayfever.

Method: We assessed BF in the first years of life in children from Leicestershire, UK. At school age (9-14 years), we performed SPT for 4 allergens (cat, dog, dust, grass) in 1515 children. A child was defined as atopic if any wheal size was >3mm. We used logistic regression, adjusting for age, sex, ethnicity, birth season, family history of atopy and socio-economic status. We stratified by maternal hayfever and investigated potential reverse causation in analysis that excluded children with eczema or wheeze in infancy.

Results: 465 (31%) children were not breastfed, 435 (29%) had BF <3 months (mo), 256 (17%) BF=4-6 mo and 348 (23%) BF >6 mo. 437 mothers (29%) had hayfever. We found no evidence for differences in risk of atopy by BF; the odds-ratios (95% confidence intervals) for BF<3 mo, BF=4-6 mo and BF>6 mo were 0.97 (0.69,1.37), 1.07 (0.72,1.59) and 1.19 (0.83,1.71), respectively, compared with no BF (p-trend=0.297). We did not find differential association by maternal hayfever (p-interaction=0.489) nor evidence for reverse causation.

Conclusion: Using objective measures and controlling for reverse causation, our study did not find evidence for an effect of breastfeeding on atopy in children of mothers either with or without hayfever. We can continue recommending breastfeeding for atopic and non-atopic mothers.

Funding: Asthma UK 07/048; SNF 3200B0-122341; SNF PDFMP3-123162.